Aperio Group LLC bought a new stake in Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 53,444 shares of the biotechnology company’s stock, valued at approximately $3,050,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of BIVV. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ during the third quarter worth about $186,000. Reliance Trust Co. of Delaware purchased a new stake in Bioverativ during the third quarter worth about $249,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in Bioverativ during the third quarter worth about $293,000. Raymond James Trust N.A. purchased a new stake in Bioverativ during the third quarter worth about $297,000. Finally, Oakbrook Investments LLC purchased a new stake in Bioverativ during the third quarter worth about $327,000. 93.07% of the stock is currently owned by institutional investors.
WARNING: “Aperio Group LLC Buys New Stake in Bioverativ Inc (BIVV)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/aperio-group-llc-buys-new-stake-in-bioverativ-inc-bivv.html.
A number of analysts have issued reports on BIVV shares. Jefferies Group LLC reiterated a “buy” rating and set a $70.00 price target (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Cowen and Company reiterated a “buy” rating and set a $80.00 price target on shares of Bioverativ in a research note on Friday, August 4th. Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Wednesday, September 20th. Zacks Investment Research lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Finally, Evercore ISI started coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $61.73.
Shares of Bioverativ Inc (NASDAQ BIVV) opened at $53.66 on Friday. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. The firm’s revenue was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ Inc will post 2.45 earnings per share for the current year.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.